Systemic Absorption and Anticholinergic Activity of Topically Applied Tropicamide

Vuori, Marja-Liisa; Kaila, Timo; Iisalo, E; Saari, K. M.

doi:10.1089/jop.1994.10.431

Cited by 35 publications

(29 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tropicamide has been used in ophthalmic clinics (Pandit & Taylor, 2000; Smith, Grzelak, Belanger, & Morgan, 1996; Vuori, Kaila, Iisalo, & Saari, 1994). However, this is the first study investigating the role for tropicamide in a model of FXS.…”

Section: Discussionmentioning

confidence: 99%

The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

Veeraragavan

Bui²,

Perkins³

et al. 2011

Behavioral Neuroscience

View full text Add to dashboard Cite

Muscarinic acetylcholine receptors (mAChR) are G-protein coupled receptors (M1-M5), grouped together into two functional classes, based on their G protein interaction. Although ubiquitously expressed in the CNS, the M4 protein shows highest expression in the neostriatum, cortex, and hippocampus. Electrophysiological and biochemical studies have provided evidence for overactive mAChR signaling in the fragile X knock-out (Fmr1KO) mouse model, and this has been hypothesized to contribute to the phenotypes seen in Fmr1KO mice. To address this hypothesis we used an M4 antagonist, tropicamide to reduce the activity through the M4 mAChR and investigated the behavioral response in the Fmr1KO animals. Data from the marble-burying assay has shown that tropicamide treatment resulted in a decreased number of marbles buried in the wild type (WT) and in the knockout (KO) animals. Results from the open field assay indicated that tropicamide increases activity in both the WT and KO mice. In the passive avoidance assay, tropicamide treatment resulted in the improvement of performance in both the WT and the KO animals at the lower doses (2 and 5 mg/kg) and the drug was shown to be important for the acquisition and not the consolidation process. Lastly, we observed that tropicamide causes a significant decrease in the percentage of audiogenic seizures in the Fmr1KO animals. These results suggested that pharmacological antagonism of the M4 receptor modulates select behavioral responses in the Fmr1 KO mice.

show abstract

Section: Discussionmentioning

confidence: 99%

The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

Veeraragavan

Bui²,

Perkins³

et al. 2011

Behavioral Neuroscience

View full text Add to dashboard Cite

show abstract

“…Therefore, the present studies focused upon the effects of tropicamide, a muscarinic ACh antagonist that shows moderate binding selectivity (i.e., fivefold) for the M4 receptor subtype (Lazareno et al 1990). Tropicamide is a muscarinic antagonist that currently is used clinically for ophthalmic purposes (Vuori et al 1994), but its potential antiparkinsonian effects are unknown. Although it is not highly selective for M4 receptors, tropicamide has been used in previous studies for assessing the functional role of muscarinic receptor subtypes (Garcia et al 2005;Lazartigues et al 1999;Parkman et al 1999;Potier and Psarropoulou 2004;Shi et al 1999;Ukai et al 2004;Iram and Hoyle 2005).…”

Section: Introductionmentioning

confidence: 99%

The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Peak plasma concentration occurs at 5 minutes Vuori et al (1994), decreasing rapidly to undetectable levels after 2 hours. Peak plasma concentration occurs at 5 minutes Vuori et al (1994), decreasing rapidly to undetectable levels after 2 hours.…”

Section: Human Pharmacokineticsmentioning

confidence: 99%

Tropicamide

Jewell

2007

xPharm: The Comprehensive Pharmacology Reference

View full text Add to dashboard Cite

Systemic Absorption and Anticholinergic Activity of Topically Applied Tropicamide

Cited by 35 publications

References 3 publications

The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

The modulation of fragile X behaviors by the muscarinic M4 antagonist, tropicamide.

The muscarinic receptor antagonist tropicamide suppresses tremulous jaw movements in a rodent model of parkinsonian tremor: possible role of M4 receptors

Tropicamide

Contact Info

Product

Resources

About